Thelansis’s “Global Hurler Syndrome (MPS I) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hurler Syndrome (MPS I) treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Hurler syndrome, the most severe form of mucopolysaccharidosis type I, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase encoded by the IDUA gene. This results in progressive intralysosomal accumulation of dermatan sulfate and heparan sulfate across multiple organ systems. Patients present in infancy with coarse facial features, hepatosplenomegaly, skeletal dysostosis multiplex, corneal clouding, and progressive neurological deterioration with cognitive regression, causing severe disability or early mortality if untreated. Diagnosis integrates elevated urinary glycosaminoglycans, deficient leukocyte enzyme activity, and confirmatory IDUA sequencing. Standard management historically relied on allogeneic hematopoietic stem cell transplantation before two years of age to prevent progressive cognitive decline, using intravenous laronidase as a somatic bridge. However, the treatment paradigm has been fundamentally transformed by autologous stem cell gene therapies like OTL-203, which provide targeted metabolic correction without the graft-versus-host risks of allogeneic transplant. Furthermore, historical intrathecal delivery investigations have been superseded by blood-brain barrier-penetrating biologics. Modern neuro-enzyme replacement therapies utilize insulin or transferrin receptor-mediated transcytosis antibody fusions, allowing systemic weekly intravenous infusions to successfully cross the blood-brain barrier and clear heparan sulfate from the central nervous system. Coordinated multidisciplinary care remains mandatory to preserve long-term survival.
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Global Hurler Syndrome (MPS I) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035 report
Our team will get in touch with you shortly about the Global Hurler Syndrome (MPS I) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035 report.